Galeotti Nicoletta
Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), Section of Pharmacology, University of Florence, Viale G. Pieraccini 6, 50139 Florence, Italy.
J Ethnopharmacol. 2017 Mar 22;200:136-146. doi: 10.1016/j.jep.2017.02.016. Epub 2017 Feb 12.
Hypericum perforatum L. (Hypericaceae), popularly called St. John's wort (SJW), has a rich historical background being one of the oldest used and most extensively investigated medicinal herbs. Many bioactivities and applications of SJW are listed in popular and in scientific literature, including antibacterial, antiviral, anti-inflammatory. In the last three decades many studies focused on the antidepressant activity of SJW extracts. However, several studies in recent years also described the antinociceptive and analgesic properties of SJW that validate the traditional uses of the plant in pain conditions.
This review provides up-to-date information on the traditional uses, pre-clinical and clinical evidence on the pain relieving activity of SJW and its active ingredients, and focuses on the possible exploitation of this plant for the management of pain.
Historical ethnobotanical publications from 1597 were reviewed for finding local and traditional uses. The relevant data on the preclinical and clinical effects of SJW were searched using various databases such as PubMed, Science Direct, Scopus, and Google Scholar. Plant taxonomy was validated by the database Plantlist.org.
Preclinical animal studies demonstrated the ability of low doses of SJW dry extracts (0.3% hypericins; 3-5% hyperforins) to induce antinociception, to relieve from acute and chronic hyperalgesic states and to augment opioid analgesia. Clinical studies (homeopathic remedies, dry extracts) highlighted dental pain conditions as a promising SJW application. In vivo and in vitro studies showed that the main components responsible for the pain relieving activity are hyperforin and hypericin. SJW analgesia appears at low doses (5-100mg/kg), minimizing the risk of herbal-drug interactions produced by hyperforin, a potent inducer of CYP enzymes.
Preclinical studies indicate a potential use of SJW in medical pain management. However, clinical research in this field is still scarce and the few studies available on chronic pain produced negative results. Prospective randomized controlled clinical trials performed at low doses are needed to validate its potential efficacy in humans.
贯叶连翘(金丝桃科),俗称圣约翰草(SJW),拥有丰富的历史背景,是最古老且使用最为广泛的药用植物之一。圣约翰草的许多生物活性和应用在通俗及科学文献中均有记载,包括抗菌、抗病毒、抗炎。在过去三十年里,许多研究聚焦于圣约翰草提取物的抗抑郁活性。然而,近年来的多项研究也描述了圣约翰草的抗伤害感受和镇痛特性,证实了该植物在疼痛病症中的传统用途。
本综述提供了关于圣约翰草传统用途、其缓解疼痛活性的临床前和临床证据及其活性成分的最新信息,并着重探讨了该植物在疼痛管理中的潜在应用。
查阅了1597年以来的历史民族植物学出版物,以探寻其在当地的传统用途。利用各种数据库,如PubMed、Science Direct、Scopus和谷歌学术搜索圣约翰草临床前和临床效果的相关数据。通过数据库Plantlist.org验证植物分类。
临床前动物研究表明,低剂量的圣约翰草干提取物(0.3%金丝桃素;3 - 5%贯叶连翘素)具有诱导抗伤害感受、缓解急慢性痛觉过敏状态以及增强阿片类镇痛的能力。临床研究(顺势疗法药物、干提取物)突出了牙科疼痛病症是圣约翰草一个有前景的应用领域。体内和体外研究表明,负责缓解疼痛活性的主要成分是贯叶连翘素和金丝桃素。圣约翰草在低剂量(5 - 100mg/kg)时即可产生镇痛作用,将由强效CYP酶诱导剂贯叶连翘素引起的草药 - 药物相互作用风险降至最低。
临床前研究表明圣约翰草在医学疼痛管理中具有潜在用途。然而,该领域的临床研究仍然匮乏,关于慢性疼痛的少数研究产生了阴性结果。需要进行低剂量的前瞻性随机对照临床试验来验证其对人类的潜在疗效。